R R

What Is Sitagliptin?

Sitagliptin is a prescription medication belonging to the dipeptidyl peptidase-4, or DPP-4, inhibitor class. It is used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. Sitagliptin is the active ingredient in Januvia and is also available in certain combination diabetes medications. It works by increasing the activity of naturally occurring hormones that help regulate insulin and glucagon release after meals. Sitagliptin is taken orally once daily, with doses adjusted for reduced kidney function. It is not approved for type 1 diabetes and does not replace insulin when insulin therapy is necessary.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Sitagliptin?

Sitagliptin is a prescription medication belonging to the dipeptidyl peptidase-4, or DPP-4, inhibitor class. It is used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. Sitagliptin is the active ingredient in Januvia and is also available in certain combination diabetes medications. It works by increasing the activity of naturally occurring hormones that help regulate insulin and glucagon release after meals. Sitagliptin is taken orally once daily, with doses adjusted for reduced kidney function. It is not approved for type 1 diabetes and does not replace insulin when insulin therapy is necessary.

read more about sitagliptin ...

Copy this HTML:

Copy HTML Copied!

How Does Sitagliptin Work?

Sitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. These hormones help regulate blood sugar after meals by stimulating insulin release when glucose levels are elevated. They also reduce inappropriate glucagon secretion, limiting glucose production by the liver. By slowing incretin breakdown, sitagliptin increases the duration of their activity and improves glucose regulation in adults with type 2 diabetes. Its actions depend partly on glucose levels, so hypoglycemia is less common when sitagliptin is taken alone than when combined with insulin or a sulfonylurea. It does not permanently cure diabetes.

What Condition Does Sitagliptin Treat?

Sitagliptin is approved to improve glycemic control in adults with type 2 diabetes when used with diet and exercise. Type 2 diabetes involves insulin resistance and impaired insulin secretion, leading to elevated blood glucose. Sitagliptin can be used alone or alongside certain other glucose-lowering medications when clinically appropriate. It is not indicated for type 1 diabetes, and its safety and effectiveness have not been established for pediatric patients. Sitagliptin has not been studied adequately in patients with a history of pancreatitis. A clinician reviews blood glucose measurements, HbA1c, kidney function, other medications, and cardiovascular history before prescribing treatment.

How Should Sitagliptin Be Taken?

Sitagliptin is taken orally once daily, with or without food. The recommended dose for adults with adequate kidney function is 100 mg daily. Patients with an estimated glomerular filtration rate of 30 to less than 45 mL/min/1.73 m? receive 50 mg once daily. Those with an estimated glomerular filtration rate below 30 mL/min/1.73 m?, including patients with end-stage kidney disease receiving dialysis, receive 25 mg once daily. Kidney function should be assessed before starting treatment and periodically afterward. Sitagliptin may be taken with other diabetes medications, but doses of insulin or insulin-stimulating medications may require adjustment to reduce hypoglycemia risk.

What Are the Side Effects and Warnings of Sitagliptin?

Common adverse effects include upper respiratory infections, nasopharyngitis, and headache. Serious risks include acute pancreatitis, kidney injury, severe allergic reactions, debilitating joint pain, and bullous pemphigoid, a blistering skin condition. Heart failure has been observed with other DPP-4 inhibitors, so patients with relevant risk factors require monitoring. Hypoglycemia risk increases when sitagliptin is used with insulin or sulfonylureas. Kidney function affects drug clearance and must be considered when selecting the dose. Persistent severe abdominal pain, facial swelling, breathing difficulties, unusual swelling or shortness of breath, or blistering skin lesions requires prompt medical assessment.

Common Questions About Sitagliptin

Is sitagliptin the same as Januvia?

Yes. Januvia contains sitagliptin, a DPP-4 inhibitor prescribed for adults with type 2 diabetes.

Can sitagliptin treat type 1 diabetes?

No. Sitagliptin is approved for adults with type 2 diabetes and should not be used as a substitute for insulin in type 1 diabetes.

Does sitagliptin require dose adjustments for kidney disease?

Yes. Patients with reduced kidney function may need 50 mg or 25 mg once daily instead of the standard 100 mg dose.

Can sitagliptin cause pancreatitis?

Yes. Acute pancreatitis, including serious cases, has been reported. Persistent severe abdominal pain requires immediate medical evaluation.

References

DailyMed - JANUVIA (sitagliptin) tablet, film coated. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=194c3718-5eb5-4cf5-85d0-2bb1ed8293b8. Date Accessed November 10, 2026.

JANUVIA Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=194c3718-5eb5-4cf5-85d0-2bb1ed8293b8. Date Accessed November 10, 2026.

Sitagliptin. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548083/. Date Accessed November 10, 2026.

Sitagliptin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a606023.html. Date Accessed November 10, 2026.

Sitagliptin. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Sitagliptin. Date Accessed November 10, 2026.